BACKGROUND: The glutamatergic modulator ketamine has created a blueprint for studying novel pharmaceuticals in the field. Recent studies suggest that "classic" serotonergic psychedelics (SPs) may also have antidepressant efficacy. Both ketamine and SPs appear to produce rapid, sustained antidepressant effects after a transient psychoactive period. METHODS: This review summarizes areas of overlap between SP and ketamine research and considers the possibility of a common, downstream mechanism of action. The therapeutic relevance of the psychoactive state, overlapping cellular and molecular effects, and overlapping electrophysiological and neuroimaging observations are all reviewed. RESULTS: Taken together, the evidence suggests a potentially shared mechanism wherein both ketamine and SPs may engender rapid neuroplastic effects in a glutamatergic activity-dependent manner. It is postulated that, though distinct, both ketamine and SPs appear to produce acute alterations in cortical network activity that may initially produce psychoactive effects and later produce milder, sustained changes in network efficiency associated with therapeutic response. However, despite some commonalities between the psychoactive component of these pharmacologically distinct therapies-such as engagement of the downstream glutamatergic pathway-the connection between psychoactive impact and antidepressant efficacy remains unclear and requires more rigorous research. CONCLUSIONS: Rapid-acting antidepressants currently under investigation may share some downstream pharmacological effects, suggesting that their antidepressant effects may come about via related mechanisms. Given the prototypic nature of ketamine research and recent progress in this area, this platform could be used to investigate entirely new classes of antidepressants with rapid and robust actions. Published by Oxford University Press on behalf of CINP 2020.
BACKGROUND: The glutamatergic modulator ketamine has created a blueprint for studying novel pharmaceuticals in the field. Recent studies suggest that "classic" serotonergic psychedelics (SPs) may also have antidepressant efficacy. Both ketamine and SPs appear to produce rapid, sustained antidepressant effects after a transient psychoactive period. METHODS: This review summarizes areas of overlap between SP and ketamine research and considers the possibility of a common, downstream mechanism of action. The therapeutic relevance of the psychoactive state, overlapping cellular and molecular effects, and overlapping electrophysiological and neuroimaging observations are all reviewed. RESULTS: Taken together, the evidence suggests a potentially shared mechanism wherein both ketamine and SPs may engender rapid neuroplastic effects in a glutamatergic activity-dependent manner. It is postulated that, though distinct, both ketamine and SPs appear to produce acute alterations in cortical network activity that may initially produce psychoactive effects and later produce milder, sustained changes in network efficiency associated with therapeutic response. However, despite some commonalities between the psychoactive component of these pharmacologically distinct therapies-such as engagement of the downstream glutamatergic pathway-the connection between psychoactive impact and antidepressant efficacy remains unclear and requires more rigorous research. CONCLUSIONS: Rapid-acting antidepressants currently under investigation may share some downstream pharmacological effects, suggesting that their antidepressant effects may come about via related mechanisms. Given the prototypic nature of ketamine research and recent progress in this area, this platform could be used to investigate entirely new classes of antidepressants with rapid and robust actions. Published by Oxford University Press on behalf of CINP 2020.
Authors: Lea J Mertens; Matthew B Wall; Leor Roseman; Lysia Demetriou; David J Nutt; Robin L Carhart-Harris Journal: J Psychopharmacol Date: 2020-01-16 Impact factor: 4.153
Authors: Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate Journal: Biol Psychiatry Date: 2012-04-21 Impact factor: 13.382
Authors: Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst Journal: J Psychopharmacol Date: 2016-12 Impact factor: 4.153
Authors: M V Uthaug; R Lancelotta; K van Oorsouw; K P C Kuypers; N Mason; J Rak; A Šuláková; R Jurok; M Maryška; M Kuchař; T Páleníček; J Riba; J G Ramaekers Journal: Psychopharmacology (Berl) Date: 2019-04-13 Impact factor: 4.530
Authors: Peter Gasser; Dominique Holstein; Yvonne Michel; Rick Doblin; Berra Yazar-Klosinski; Torsten Passie; Rudolf Brenneisen Journal: J Nerv Ment Dis Date: 2014-07 Impact factor: 2.254
Authors: Calvin Ly; Alexandra C Greb; Lindsay P Cameron; Jonathan M Wong; Eden V Barragan; Paige C Wilson; Kyle F Burbach; Sina Soltanzadeh Zarandi; Alexander Sood; Michael R Paddy; Whitney C Duim; Megan Y Dennis; A Kimberley McAllister; Kassandra M Ori-McKenney; John A Gray; David E Olson Journal: Cell Rep Date: 2018-06-12 Impact factor: 9.423
Authors: Giordano Novak Rossi; Jaime E C Hallak; Glen Baker; Serdar M Dursun; Rafael G Dos Santos Journal: Eur Arch Psychiatry Clin Neurosci Date: 2022-07-13 Impact factor: 5.760
Authors: Peter M Lambert; Richard Ni; Ann Benz; Nicholas R Rensing; Michael Wong; Charles F Zorumski; Steven Mennerick Journal: Neuropsychopharmacology Date: 2022-09-27 Impact factor: 8.294
Authors: Ling-Xiao Shao; Clara Liao; Ian Gregg; Pasha A Davoudian; Neil K Savalia; Kristina Delagarza; Alex C Kwan Journal: Neuron Date: 2021-07-05 Impact factor: 18.688
Authors: John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157
Authors: Joshua T Kantrowitz; Zhengchao Dong; Matthew S Milak; Rain Rashid; Lawrence S Kegeles; Daniel C Javitt; Jeffrey A Lieberman; J John Mann Journal: Transl Psychiatry Date: 2021-08-05 Impact factor: 6.222